Advanced Search
Contact | Corporate | Help

Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma

Sponsors:
  • European Organization for Research and Treatment of Cancer - EORTC
Phases:
  • Phase III
IndicationsAcronym:
  • Lymphoma
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: bortezomib
  • Drug: vorinostat
  • Other: laboratory biomarker analysis
Enrollment:
189

Additional information about NCT01386398.


SourceSolution © 2008-2012